Additionally, according to the Prostate Cancer Working Group 2, patients must present with prostate-specific antigen (PSA) progression at an increase of 25% from nadir at a minimum rise of 2ng/mL and confirmed with a second value (1, 2). The gene discussed is KLK3; the disease is Familial prostate cancer.